-
1
-
-
84940008999
-
US Department of Health and Human Services panel on antiretroviral guidelines for adults and adolescents
-
Accessed 9 Feb 2015
-
US Department of Health and Human Services panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2014. http://aidsinfo.nih.gov/guidelines. Accessed 9 Feb 2015.
-
(2014)
Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents
-
-
-
2
-
-
84890494817
-
British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (updated November 2013)
-
Williams DI, Churchill D, Anderson J, et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (updated November 2013). HIV Med. 2014;15(Suppl 1):1-85.
-
(2014)
HIV Med.
, vol.15
, pp. 1-85
-
-
Williams, D.I.1
Churchill, D.2
Anderson, J.3
-
3
-
-
84904568743
-
Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel
-
25038359
-
Günthard HF, Aberg JA, Eron JJ, et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA. 2014;312(4):410-25.
-
(2014)
JAMA.
, vol.312
, Issue.4
, pp. 410-425
-
-
Günthard, H.F.1
Aberg, J.A.2
Eron, J.J.3
-
5
-
-
84861689822
-
Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel
-
W-284-94
-
Thompson MA, Mugavero MJ, Amico KR, et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann Intern Med. 2012;156(11):817-33, W-284-94.
-
(2012)
Ann Intern Med
, vol.156
, Issue.11
, pp. 817-33
-
-
Thompson, M.A.1
Mugavero, M.J.2
Amico, K.R.3
-
6
-
-
84880611713
-
Spillover adherence effects of fixed-dose combination HIV therapy
-
3295624 22399848
-
Kauf TL, Davis KL, Earnshaw SR, et al. Spillover adherence effects of fixed-dose combination HIV therapy. Patient Prefer Adherence. 2012;6:155-64.
-
(2012)
Patient Prefer Adherence.
, vol.6
, pp. 155-164
-
-
Kauf, T.L.1
Davis, K.L.2
Earnshaw, S.R.3
-
7
-
-
84864670297
-
Once-daily single-tablet regimens: a long and winding road to excellence in antiretroviral treatment
-
22833060
-
Llibre JM, Clotet B. Once-daily single-tablet regimens: a long and winding road to excellence in antiretroviral treatment. AIDS Rev. 2012;14(3):168-78.
-
(2012)
AIDS Rev.
, vol.14
, Issue.3
, pp. 168-178
-
-
Llibre, J.M.1
Clotet, B.2
-
8
-
-
84977119451
-
Single-tablet regimens in HIV therapy
-
4108118 25134808
-
Astuti N, Maggiolo F. Single-tablet regimens in HIV therapy. Infect Dis Ther. 2014;3(1):1-17.
-
(2014)
Infect Dis Ther.
, vol.3
, Issue.1
, pp. 1-17
-
-
Astuti, N.1
Maggiolo, F.2
-
12
-
-
84904740227
-
Dolutegravir: a review of its use in the management of HIV-1 infection in adolescents and adults
-
1:CAS:528:DC%2BC2cXhtFCqsbfN 25005775
-
McCormack PL. Dolutegravir: a review of its use in the management of HIV-1 infection in adolescents and adults. Drugs. 2014;74(11):1241-52.
-
(2014)
Drugs.
, vol.74
, Issue.11
, pp. 1241-1252
-
-
McCormack, P.L.1
-
13
-
-
80052847538
-
Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572)
-
3187526 1:CAS:528:DC%2BC3MXhs1ansbvI 21719464
-
Hare S, Smith SJ, Métifiot M, et al. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol. 2011;80(4):565-72.
-
(2011)
Mol Pharmacol.
, vol.80
, Issue.4
, pp. 565-572
-
-
Hare, S.1
Smith, S.J.2
Métifiot, M.3
-
14
-
-
78751697293
-
In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor
-
3028777 1:CAS:528:DC%2BC3MXisVyjt7g%3D 21115794
-
Kobayashi M, Yoshinaga T, Seki T, et al. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother. 2011;55(2):813-21.
-
(2011)
Antimicrob Agents Chemother.
, vol.55
, Issue.2
, pp. 813-821
-
-
Kobayashi, M.1
Yoshinaga, T.2
Seki, T.3
-
15
-
-
12444279985
-
Abacavir plus lamivudine
-
1:CAS:528:DC%2BD2MXhsFersrw%3D 15631548
-
Dando T, Scott L. Abacavir plus lamivudine. Drugs. 2005;65(2):285-302.
-
(2005)
Drugs.
, vol.65
, Issue.2
, pp. 285-302
-
-
Dando, T.1
Scott, L.2
-
16
-
-
84905984152
-
Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor dolutegravir in human primary macrophages and lymphocytes
-
1:CAS:528:DC%2BC2MXis12qsbo%3D 24860155
-
Pollicita M, Surdo M, Di Santo F, et al. Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor dolutegravir in human primary macrophages and lymphocytes. J Antimicrob Chemother. 2014;69(9):2412-9.
-
(2014)
J Antimicrob Chemother.
, vol.69
, Issue.9
, pp. 2412-2419
-
-
Pollicita, M.1
Surdo, M.2
Di Santo, F.3
-
19
-
-
84887052771
-
Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection [plus supplementary appendix]
-
1:CAS:528:DC%2BC3sXhslGhtLfE 24195548
-
Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection [plus supplementary appendix]. N Engl J Med. 2013;369(19):1807-18.
-
(2013)
N Engl J Med.
, vol.369
, Issue.19
, pp. 1807-1818
-
-
Walmsley, S.L.1
Antela, A.2
Clumeck, N.3
-
20
-
-
84904546476
-
Dolutegravir regimen statistically superior to tenofovir/emtricitabine/efavirenz: 96-wk data from the SINGLE study (ING114467) [abstract no. 543 plus poster]
-
Walmsley S, Berenguer J, Khuong-Josses MA. Dolutegravir regimen statistically superior to tenofovir/emtricitabine/efavirenz: 96-wk data from the SINGLE study (ING114467) [abstract no. 543 plus poster]. Top Antivir Med. 2014;22(e-1):261-2.
-
(2014)
Top Antivir Med
, vol.22
, Issue.e-1
, pp. 261-262
-
-
Walmsley, S.1
Berenguer, J.2
Khuong-Josses, M.A.3
-
21
-
-
84885948765
-
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial
-
1:CAS:528:DC%2BC3sXhsFeltLzJ 24074642
-
Raffi F, Jaeger H, Quiros-Roldan E, et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2013;13(11):927-35.
-
(2013)
Lancet Infect Dis.
, vol.13
, Issue.11
, pp. 927-935
-
-
Raffi, F.1
Jaeger, H.2
Quiros-Roldan, E.3
-
22
-
-
84882912698
-
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study
-
1:CAS:528:DC%2BC3sXhtVKrur7I 23830355
-
Cahn P, Pozniak AL, Mingrone H, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet. 2013;382(9893):700-8.
-
(2013)
Lancet.
, vol.382
, Issue.9893
, pp. 700-708
-
-
Cahn, P.1
Pozniak, A.L.2
Mingrone, H.3
-
23
-
-
84903303497
-
Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study
-
1:CAS:528:DC%2BC2cXltl2gt7k%3D 24698485
-
Clotet B, Feinberg J, van Lunzen J, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet. 2014;383(9936):2222-31.
-
(2014)
Lancet.
, vol.383
, Issue.9936
, pp. 2222-2231
-
-
Clotet, B.1
Feinberg, J.2
Van Lunzen, J.3
-
24
-
-
47949114939
-
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection
-
1:CAS:528:DC%2BD1cXovFSqtb8%3D 18650513
-
Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med. 2008;359(4):355-65.
-
(2008)
N Engl J Med.
, vol.359
, Issue.4
, pp. 355-365
-
-
Cooper, D.A.1
Steigbigel, R.T.2
Gatell, J.M.3
-
25
-
-
84861136225
-
Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens
-
3370736 1:CAS:528:DC%2BC38XnslWrsLY%3D 22450969
-
Garrido C, Villacian J, Zahonero N, et al. Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens. Antimicrob Agents Chemother. 2012;56(6):2873-8.
-
(2012)
Antimicrob Agents Chemother.
, vol.56
, Issue.6
, pp. 2873-2878
-
-
Garrido, C.1
Villacian, J.2
Zahonero, N.3
-
26
-
-
80052847754
-
Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes
-
3187001 1:CAS:528:DC%2BC3MXhtl2ns7fF 21807982
-
Hightower KE, Wang R, DeAnda F, et al. Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrob Agents Chemother. 2011;55(10):4552-9.
-
(2011)
Antimicrob Agents Chemother.
, vol.55
, Issue.10
, pp. 4552-4559
-
-
Hightower, K.E.1
Wang, R.2
DeAnda, F.3
-
27
-
-
80155188567
-
Cross-resistance profile of the novel integrase inhibitor dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir
-
1:CAS:528:DC%2BC3MXhtlyqt7vN 21984737
-
Canducci F, Ceresola ER, Boeri E, et al. Cross-resistance profile of the novel integrase inhibitor dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir. J Infect Dis. 2011;204(11):1811-5.
-
(2011)
J Infect Dis.
, vol.204
, Issue.11
, pp. 1811-1815
-
-
Canducci, F.1
Ceresola, E.R.2
Boeri, E.3
-
28
-
-
84904721700
-
Impact of raltegravir/elvitegravir selected mutations on dolutegravir cross-resistance [abstract no. 595]
-
Huang W, Frantzell A, Whitcomb JM. Impact of raltegravir/elvitegravir selected mutations on dolutegravir cross-resistance [abstract no. 595]. Top Antivir Med. 2014;22(e-1):292-3.
-
(2014)
Top Antivir Med
, vol.22
, Issue.e-1
, pp. 292-293
-
-
Huang, W.1
Frantzell, A.2
Whitcomb, J.M.3
-
29
-
-
84929755856
-
Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients
-
Fourati S, Charpentier C, Amiel C, et al. Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients. J Antimicrob Chemother. 2015. doi: 10.1093/jac/dku535.
-
(2015)
J Antimicrob Chemother.
-
-
Fourati, S.1
Charpentier, C.2
Amiel, C.3
-
30
-
-
84898987717
-
Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study
-
4091579 1:CAS:528:DC%2BC2cXht1ygtrjL 24446523
-
Castagna A, Maggiolo F, Penco G, et al. Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis. 2014;210(3):354-62.
-
(2014)
J Infect Dis.
, vol.210
, Issue.3
, pp. 354-362
-
-
Castagna, A.1
Maggiolo, F.2
Penco, G.3
-
31
-
-
84904559099
-
New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors
-
1:CAS:528:DC%2BC2cXht1SqsbfM 24710029
-
Malet I, Gimferrer Arriaga L, Artese A, et al. New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors. J Antimicrob Chemother. 2014;69(8):2118-22.
-
(2014)
J Antimicrob Chemother.
, vol.69
, Issue.8
, pp. 2118-2122
-
-
Malet, I.1
Gimferrer Arriaga, L.2
Artese, A.3
-
33
-
-
84905735621
-
2014 Update of the drug resistance mutations in HIV-1
-
25101529
-
Wensing AM, Calvez V, Gunthard HF, et al. 2014 Update of the drug resistance mutations in HIV-1. Top Antivir Med. 2014;22(3):642-50.
-
(2014)
Top Antivir Med.
, vol.22
, Issue.3
, pp. 642-650
-
-
Wensing, A.M.1
Calvez, V.2
Gunthard, H.F.3
-
34
-
-
84862883245
-
Effect of a single supratherapeutic dose of dolutegravir on cardiac repolarization
-
1:CAS:528:DC%2BC38XntVyms74%3D 22422361
-
Chen S, Min SS, Peppercorn A, et al. Effect of a single supratherapeutic dose of dolutegravir on cardiac repolarization. Pharmacotherapy. 2012;32(4):333-9.
-
(2012)
Pharmacotherapy.
, vol.32
, Issue.4
, pp. 333-339
-
-
Chen, S.1
Min, S.S.2
Peppercorn, A.3
-
35
-
-
84874431501
-
A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects
-
3612717 1:CAS:528:DC%2BC3sXktFOgtL8%3D 22905856
-
Koteff J, Borland J, Chen S, et al. A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects. Br J Clin Pharmacol. 2013;75(4):990-6.
-
(2013)
Br J Clin Pharmacol.
, vol.75
, Issue.4
, pp. 990-996
-
-
Koteff, J.1
Borland, J.2
Chen, S.3
-
36
-
-
84861710765
-
Changes in body composition and mitochondrial DNA in HIV-1-infected patients switching to fixed-dose abacavir/lamivudine or tenofovir/emtricitabine: a substudy of the BICOMBO trial
-
1:CAS:528:DC%2BC38XhtFSqs7bL 22374987
-
Curran A, Martinez E, Podzamczer D, et al. Changes in body composition and mitochondrial DNA in HIV-1-infected patients switching to fixed-dose abacavir/lamivudine or tenofovir/emtricitabine: a substudy of the BICOMBO trial. Antivir Ther. 2012;17(4):711-8.
-
(2012)
Antivir Ther.
, vol.17
, Issue.4
, pp. 711-718
-
-
Curran, A.1
Martinez, E.2
Podzamczer, D.3
-
37
-
-
84973228435
-
48 week bone marker changes with dolutegravir (DTG) plus abacavir/lamivudine (ABC/3TC) vs. tenofovir/emtricitabine/efavirenz (EFV/TDF/FTC): the SINGLE trial [abstract no. P72]
-
Yazdanpanah Y, Khuong-Josses M, Hocqueloux L, et al. 48 week bone marker changes with dolutegravir (DTG) plus abacavir/lamivudine (ABC/3TC) vs. tenofovir/emtricitabine/efavirenz (EFV/TDF/FTC): the SINGLE trial [abstract no. P72]. BMC Infect Dis. 2014;14(Suppl 2):30.
-
(2014)
BMC Infect Dis.
, vol.14
, pp. 30
-
-
Yazdanpanah, Y.1
Khuong-Josses, M.2
Hocqueloux, L.3
-
38
-
-
84923689874
-
Abacavir and lamivudine exposures during pregnancy and non-defect adverse pregnancy outcomes: data from the Antiretroviral Pregnancy Registry
-
Vannappagari V, Koram N, Albano J, et al. Abacavir and lamivudine exposures during pregnancy and non-defect adverse pregnancy outcomes: data from the Antiretroviral Pregnancy Registry. J Acquir Immune Defic Syndr. 2014. doi: 10.1097/QAI.0000000000000465.
-
(2014)
J Acquir Immune Defic Syndr
-
-
Vannappagari, V.1
Koram, N.2
Albano, J.3
-
39
-
-
84903776448
-
Bioequivalence of a dolutegravir, abacavir, and lamivudine fixed-dose combination tablet and the effect of food
-
1:CAS:528:DC%2BC2cXhtFSrtL7N 24798770
-
Weller S, Chen S, Borland J, et al. Bioequivalence of a dolutegravir, abacavir, and lamivudine fixed-dose combination tablet and the effect of food. J Acquir Immune Defic Syndr. 2014;66(4):393-8.
-
(2014)
J Acquir Immune Defic Syndr.
, vol.66
, Issue.4
, pp. 393-398
-
-
Weller, S.1
Chen, S.2
Borland, J.3
-
40
-
-
84964314604
-
ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects
-
4166983 24944232
-
Letendre SL, Mills AM, Tashima KT, et al. ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects. Clin Infect Dis. 2014;59(7):1032-7.
-
(2014)
Clin Infect Dis.
, vol.59
, Issue.7
, pp. 1032-1037
-
-
Letendre, S.L.1
Mills, A.M.2
Tashima, K.T.3
-
41
-
-
19544370354
-
Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid
-
1140502 1:CAS:528:DC%2BD2MXkvFCgsbo%3D 15917556
-
Capparelli EV, Letendre SL, Ellis RJ, et al. Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid. Antimicrob Agents Chemother. 2005;49(6):2504-6.
-
(2005)
Antimicrob Agents Chemother.
, vol.49
, Issue.6
, pp. 2504-2506
-
-
Capparelli, E.V.1
Letendre, S.L.2
Ellis, R.J.3
-
42
-
-
84893485078
-
Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV-negative women
-
4038682 1:CAS:528:DC%2BC2cXlvFymsr8%3D 23899439
-
Adams JL, Patterson KB, Prince HM, et al. Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV-negative women. Antivir Ther. 2013;18(8):1005-13.
-
(2013)
Antivir Ther.
, vol.18
, Issue.8
, pp. 1005-1013
-
-
Adams, J.L.1
Patterson, K.B.2
Prince, H.M.3
-
43
-
-
84883385762
-
Dolutegravir pharmacokinetics in the genital tract and colorectum of HIV-negative men after single and multiple dosing
-
3804901 1:CAS:528:DC%2BC3sXht12jtL3L 23945251
-
Greener BN, Patterson KB, Prince HMA, et al. Dolutegravir pharmacokinetics in the genital tract and colorectum of HIV-negative men after single and multiple dosing. J Acquir Immune Defic Syndr. 2013;64(1):39-44.
-
(2013)
J Acquir Immune Defic Syndr.
, vol.64
, Issue.1
, pp. 39-44
-
-
Greener, B.N.1
Patterson, K.B.2
Prince, H.M.A.3
-
44
-
-
84880268976
-
Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans
-
3719771 1:CAS:528:DC%2BC3sXht1Wgtb%2FO 23669385
-
Castellino S, Moss L, Wagner D, et al. Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans. Antimicrob Agents Chemother. 2013;57(8):3536-46.
-
(2013)
Antimicrob Agents Chemother.
, vol.57
, Issue.8
, pp. 3536-3546
-
-
Castellino, S.1
Moss, L.2
Wagner, D.3
-
45
-
-
0029952016
-
Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction
-
163359,1:CAS:528:DyaK28XjtlWmur8%3D 8726029
-
Heald AE, Hsyu PH, Yuen GJ, et al. Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction. Antimicrob Agents Chemother. 1996;40(6):1514-9.
-
(1996)
Antimicrob Agents Chemother.
, vol.40
, Issue.6
, pp. 1514-1519
-
-
Heald, A.E.1
Hsyu, P.H.2
Yuen, G.J.3
-
46
-
-
84890448894
-
Evaluation of the effect of UGT1A1 polymorphisms on dolutegravir pharmacokinetics
-
1:CAS:528:DC%2BC3sXhvFensr3E 24329186
-
Chen S, St Jean P, Borland J, et al. Evaluation of the effect of UGT1A1 polymorphisms on dolutegravir pharmacokinetics. Pharmacogenomics. 2014;15(1):9-16.
-
(2014)
Pharmacogenomics.
, vol.15
, Issue.1
, pp. 9-16
-
-
Chen, S.1
St Jean, P.2
Borland, J.3
-
47
-
-
84921304009
-
Dolutegravir (DTG) + abacavir/lamivudine once daily superior to tenofovir/emtricitabine/efavirenz in treatment naive HIV subjects: 144-week results from SINGLE (ING114467) [abstract no. H-647a]
-
Pappa K, Baumgarten A, Felizarta F, et al. Dolutegravir (DTG) + abacavir/lamivudine once daily superior to tenofovir/emtricitabine/efavirenz in treatment naive HIV subjects: 144-week results from SINGLE (ING114467) [abstract no. H-647a]. In: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy. 2014.
-
(2014)
54th Interscience Conference on Antimicrobial Agents and Chemotherapy
-
-
Pappa, K.1
Baumgarten, A.2
Felizarta, F.3
-
48
-
-
84874411899
-
Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study
-
1:CAS:528:DC%2BC3sXnslyjtA%3D%3D 23306000
-
Raffi F, Rachlis A, Stellbrink H-J, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013;381(9868):735-43.
-
(2013)
Lancet.
, vol.381
, Issue.9868
, pp. 735-743
-
-
Raffi, F.1
Rachlis, A.2
Stellbrink, H.-J.3
-
49
-
-
84929260080
-
Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naive HIV-1-positive individuals: 96 week results from FLAMINGO [abstract no. O153]
-
4224885, 25393999
-
Molina JM, Clotet B, van Lunzen J, et al. Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naive HIV-1-positive individuals: 96 week results from FLAMINGO [abstract no. O153]. J Int AIDS Soc. 2014;17(Suppl 3):19490.
-
(2014)
J Int AIDS Soc.
, vol.17
, pp. 19490
-
-
Molina, J.M.1
Clotet, B.2
Van Lunzen, J.3
-
50
-
-
84920262900
-
Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials
-
4284010 1:CAS:528:DC%2BC2cXitFKqsLvF 25387312
-
Raffi F, Rachlis A, Brinson C, et al. Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials. AIDS. 2015;29(2):167-74.
-
(2015)
AIDS.
, vol.29
, Issue.2
, pp. 167-174
-
-
Raffi, F.1
Rachlis, A.2
Brinson, C.3
-
52
-
-
84939939065
-
An indirect comparison of efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir and dolutegravir + abacavir/lamivudine [abstract no. P247]
-
4225386, 25397523
-
Rogatto F, Bouee S, Jeanbat V, et al. An indirect comparison of efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir and dolutegravir + abacavir/lamivudine [abstract no. P247]. J Int AIDS Soc. 2014;17(Suppl 3):19779.
-
(2014)
J Int AIDS Soc.
, vol.17
, pp. 19779
-
-
Rogatto, F.1
Bouee, S.2
Jeanbat, V.3
-
54
-
-
84884554042
-
Association between daily antiretroviral pill burden and treatment adherence, hospitalisation risk, and other healthcare utilisation and costs in a US medicaid population with HIV
-
Cohen CJ, Meyers JL, Davis KL. Association between daily antiretroviral pill burden and treatment adherence, hospitalisation risk, and other healthcare utilisation and costs in a US medicaid population with HIV. BMJ Open. 2013;3(8). doi: 10.1136/bmjopen-2013-003028.
-
(2013)
BMJ Open
, vol.3
, Issue.8
-
-
Cohen, C.J.1
Meyers, J.L.2
Davis, K.L.3
-
55
-
-
84891110614
-
Cost analysis of initial highly active antiretroviral therapy regimens for managing human immunodeficiency virus-infected patients according to clinical practice in a hospital setting
-
3872009, 24379676
-
Colombo GL, Castagna A, Di Matteo S, et al. Cost analysis of initial highly active antiretroviral therapy regimens for managing human immunodeficiency virus-infected patients according to clinical practice in a hospital setting. Ther Clin Risk Manag. 2014;10:9-15.
-
(2014)
Ther Clin Risk Manag.
, vol.10
, pp. 9-15
-
-
Colombo, G.L.1
Castagna, A.2
Di Matteo, S.3
|